A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
T. R. Jeffry Evans,Bristi Basu,Richard Hubner,Yuk Ting Ma,Tim Meyer,Daniel H. Palmer, David J. James Pinato,Elizabeth Ruth Plummer,Paul J. Ross,Adel Samson,Debashis Sarker,Timothy Kendall,Christopher Bellamy,Helen L. Reeves, Fiona Thomson, Claire A. Lawless,Jamie Stobo, Owen J. Sansom,Derek A. Mann,Thomas G. Bird JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
